Showing results (11-20 of 111) with videos related to

Sort By:
Pageof 12
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2018
Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation OutcomesLucie M Turcotte, Tao Wang, Michael T Hemmer, et al.
American Journal of Epidemiology|May 5, 2017
Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-LearningElizabeth F Krakow, Michael Hemmer, Tao Wang, et al.
Blood Advances|January 11, 2023
Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor typeRohtesh S Mehta, David Marin, Amin Alousi, et al.
American Journal of Infection Control|July 28, 2022
Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic: Lessons learnedFareed Khawaja, Krithika Srinivasan, Amy Spallone, et al.
American Journal of Hematology|June 11, 2013
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilizationVeronica R Smith, Uday Popat, Stefan Ciurea, et al.
Transplantation and Cellular Therapy|March 29, 2023
Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid LeukemiaRohtesh S Mehta, Jeremy Ramdial, David Marin, et al.
Blood|July 27, 2007
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemiaPartow Kebriaei, Michelle A Detry, Sergio Giralt, et al.
Blood Advances|April 12, 2024
Long-term outcomes after haploidentical stem cell transplantation for hematologic malignanciesSupawee Saengboon, Stefan Ciurea, Uday Popat, et al.
Transplantation and Cellular Therapy|June 1, 2026
A Phase Ib Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantationShukaib Arslan, Corey Cutler, Amin Alousi, et al.
Blood|August 23, 2014
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHDIssa F Khouri, Wei Wei, Martin Korbling, et al.
Pageof 12